Lytix Biopharma AS 6BG.F Stock
Lytix Biopharma AS Price Chart
Lytix Biopharma AS 6BG.F Financial and Trading Overview
| Lytix Biopharma AS stock price | 0.76 EUR |
| Previous Close | 0.69 EUR |
| Open | 0.69 EUR |
| Bid | 0.72 EUR x N/A |
| Ask | 0.74 EUR x N/A |
| Day's Range | 0.69 - 0.69 EUR |
| 52 Week Range | 0.52 - 1.04 EUR |
| Volume | 2.88K EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 27.52M EUR |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.19 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
6BG.F Valuation Measures
| Enterprise Value | -99124544 EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.5963979 |
| Price/Book (mrq) | 0.20314354 |
| Enterprise Value/Revenue | -12.956 |
| Enterprise Value/EBITDA | N/A |
Trading Information
Lytix Biopharma AS Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -21.28% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.04 EUR |
| 52 Week Low | 0.52 EUR |
| 50-Day Moving Average | 0.68 EUR |
| 200-Day Moving Average | 0.74 EUR |
6BG.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 40.07M |
| Float | 17.31M |
| Short Ratio | N/A |
| % Held by Insiders | 65.91% |
| % Held by Institutions | 0.78% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -986.72% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -29.35% |
| Return on Equity (ttm) | -41.50% |
Income Statement
| Revenue (ttm) | 7.65M EUR |
| Revenue Per Share (ttm) | 0.19 EUR |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 7.65M EUR |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -60448000 EUR |
| Diluted EPS (ttm) | -0.12 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 126.37M EUR |
| Total Cash Per Share (mrq) | 3.15 EUR |
| Total Debt (mrq) | 0 EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 7.805 |
| Book Value Per Share (mrq) | 3.372 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -54160000 EUR |
| Levered Free Cash Flow (ttm) | -41028752 EUR |
Profile of Lytix Biopharma AS
| Country | Germany |
| State | N/A |
| City | Oslo |
| Address | Sandakerveien 138 |
| ZIP | 0484 |
| Phone | N/A |
| Website | https://www.lytixbiopharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products also include LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. The company was incorporated in 2003 and is based in Oslo, Norway.
Q&A For Lytix Biopharma AS Stock
What is a current 6BG.F stock price?
Lytix Biopharma AS 6BG.F stock price today per share is 0.76 EUR.
How to purchase Lytix Biopharma AS stock?
You can buy 6BG.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Lytix Biopharma AS?
The stock symbol or ticker of Lytix Biopharma AS is 6BG.F.
Which industry does the Lytix Biopharma AS company belong to?
The Lytix Biopharma AS industry is Biotechnology.
How many shares does Lytix Biopharma AS have in circulation?
The max supply of Lytix Biopharma AS shares is 51.76M.
What is Lytix Biopharma AS Price to Earnings Ratio (PE Ratio)?
Lytix Biopharma AS PE Ratio is now.
What was Lytix Biopharma AS earnings per share over the trailing 12 months (TTM)?
Lytix Biopharma AS EPS is -0.19 EUR over the trailing 12 months.
Which sector does the Lytix Biopharma AS company belong to?
The Lytix Biopharma AS sector is Healthcare.